<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" nameag="viewport"/>
<title>Retina</title>
<script src="https://cdn.tailwindcss.com"></script>
<script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
<script src="https://cdn.jsdelivr.net/npm/canvas-confetti@1.6.0/dist/confetti.browser.min.js"></script>
<style>
        /* Custom styles for enhanced aesthetics and responsiveness */
        .option-btn {
            transition: all 0.3s ease;
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
        }
        .option-btn:hover, .option-btn:active {
            transform: scale(1.02);
            box-shadow: 0 4px 8px rgba(0, 0, 0, 0.2);
        }
        .option-btn.selected {
            background-color: #3b82f6;
            color: white;
        }
        .marked {
            background-color: #fef08a;
        }
        .progress-bar {
            transition: width 0.5s ease-in-out;
            background: linear-gradient(to right, #3b82f6, #22c55e);
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.2);
            animation: pulse 2s infinite;
        }
        @keyframes pulse {
            0% { opacity: 1; }
            50% { opacity: 0.8; }
            100% { opacity: 1; }
        }
        .question-nav-btn, .result-nav-btn-grid {
            width: 40px;
            height: 40px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 8px;
            font-size: 16px;
            touch-action: manipulation;
            transition: all 0.2s ease;
        }
        .question-nav-btn:hover, .question-nav-btn:active, .result-nav-btn-grid:hover, .result-nav-btn-grid:active {
            transform: scale(1.05);
        }
        .answered {
            background-color: #22c55e;
            color: white;
        }
        .unanswered {
            background-color: #e5e7eb;
        }
        .marked-nav {
            border: 2px solid #fef08a;
        }
        .video-container, .audio-container {
            display: none;
            position: relative;
        }
        .video-container.active, .audio-container.active {
            display: block;
            animation: fadeIn 0.5s ease-in;
        }
        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }
        .section-transition {
            transition: opacity 0.3s ease;
        }
        .section-transition.hidden {
            opacity: 0;
            pointer-events: none;
        }
        .result-nav {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-top: 1rem;
        }
        .result-nav-btn {
            background-color: #4b5563;
            color: white;
            padding: 0.5rem 1rem;
            border-radius: 8px;
            transition: all 0.2s ease;
        }
        .result-nav-btn:hover, .result-nav-btn:active {
            background-color: #374151;
            transform: scale(1.05);
        }
        .result-nav-btn:disabled {
            background-color: #d1d5db;
            cursor: not-allowed;
        }
        .error-message {
            color: #dc2626;
            font-weight: bold;
            margin-top: 1rem;
        }
        /* Mobile-specific adjustments */
        @media (max-width: 640px) {
            .question-nav-btn, .result-nav-btn-grid {
                width: 38px;
                height: 38px;
                font-size: 14px;
            }
            .nav-panel, .results-nav-panel {
                width: 100%;
                max-width: 100%;
                overscroll-behavior: contain;
            }
            .option-btn {
                padding: 12px;
                font-size: 14px;
            }
            .header-text {
                font-size: 1.5rem;
            }
            .subheader-text {
                font-size: 0.875rem;
            }
            .button-group, .result-nav {
                flex-direction: column;
                gap: 0.5rem;
            }
            .result-nav-btn {
                width: 100%;
                text-align: center;
            }
        }
        /* Dark mode styles */
        .dark .bg-gray-100 {
            background-color: #1f2937;
        }
        .dark .bg-white {
            background-color: #374151;
        }
        .dark .text-gray-700 {
            color: #d1d5db;
        }
        .dark .text-gray-800 {
            color: #e5e7eb;
        }
        .dark .bg-gray-200 {
            background-color: #4b5563;
        }
        .dark .border {
            border-color: #4b5563;
        }
        .dark .bg-blue-500 {
            background-color: #2563eb;
        }
        .dark .hover\:bg-blue-600:hover {
            background-color: #1d4ed8;
        }
        .dark .bg-yellow-300 {
            background-color: #b45309;
            color: white;
        }
        .dark .hover\:bg-yellow-400:hover {
            background-color: #92400e;
        }
        .dark .bg-green-500 {
            background-color: #15803d;
        }
        .dark .hover\:bg-green-600:hover {
            background-color: #166534;
        }
        .dark .bg-gray-500 {
            background-color: #4b5563;
        }
        .dark .hover\:bg-gray-600:hover {
            background-color: #374151;
        }
        .dark .result-nav-btn, .dark .result-nav-btn-grid {
            background-color: #2563eb;
        }
        .dark .result-nav-btn:hover, .dark .result-nav-btn:active, .dark .result-nav-btn-grid:hover, .dark .result-nav-btn-grid:active {
            background-color: #1d4ed8;
        }
        .dark .result-nav-btn:disabled, .dark .result-nav-btn-grid:disabled {
            background-color: #4b5563;
        }
        .video-placeholder {
            width: 400px;
            height: 300px;
            background-color: #f0f0f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            margin-top: 10px;
            border-radius: 8px;
            border: 1px solid #ccc;
        }
        .play-icon {
            font-size: 40px;
            color: #007bff;
        }
        .video-loading {
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            border: 4px solid #f3f3f3;
            border-top: 4px solid #3b82f6;
            border-radius: 50%;
            width: 40px;
            height: 40px;
            animation: spin 1s linear infinite;
        }
        @keyframes spin {
            0% { transform: translate(-50%, -50%) rotate(0deg); }
            100% { transform: translate(-50%, -50%) rotate(360deg); }
        }
    </style>

<script>
    // --- GEMINI AUTO-CAPTURE LISTENER ---
    // This function runs immediately after the quiz determines an answer is INCORRECT.
    function captureMistake(questionIndex, questionsData) {
        try {
            const item = questionsData[questionIndex];
            // Use the question text as a unique, stable identifier
            const uniqueId = 'srs_quiz_' + btoa(item.text.substring(0, 50)).replace(/=/g, ''); 

            // 1. Clean and simplify the explanation for storage
            let explanationText = item.explanation || item.correct_answer || "No explanation provided.";
            
            // Strip complex HTML (images, lists) and boilerplate text
            explanationText = explanationText.replace(/<img[^>]*>/g, "[IMAGE]").trim(); // Replace images with placeholder
            explanationText = explanationText.replace(/<p><strong>Ans\. [A-Z]\).*/i, "").trim(); // Remove the repeated Answer line
            explanationText = explanationText.replace(/<p><strong>Educational Objective:<\/strong>.*?<\/p>/gs, "").trim(); // Remove EO block
            explanationText = explanationText.replace(/@dams_new_robot/g, "");
            explanationText = explanationText.replace(/<\/?[^>]+(>|$)/g, " ").trim(); // Final strip of remaining tags

            // 2. Prepare card data
            const cardData = {
                text: item.text,
                answer: item.correct_answer,
                explanation: explanationText.substring(0, 500), // Keep explanations short
                nextReview: 0, // Due immediately
                reviews: 0,
                source: document.title.split('-')[0].trim() || 'Quiz'
            };

            // 3. Save to Local Storage (SRS Bank)
            localStorage.setItem(uniqueId, JSON.stringify(cardData));
            
            console.log(`ðŸ§  Captured Mistake #${questionIndex + 1} from ${document.title}`);

        } catch (e) {
            console.error("SRS Capture Failed:", e);
        }
    }
    // --- END GEMINI AUTO-CAPTURE LISTENER ---
</script>

</head>
<body class="bg-gray-100 font-sans transition-colors duration-300 min-h-screen overflow-y-auto">
<!-- Header Section -->
<header class="bg-blue-600 text-white p-4 shadow-lg">
<div class="container mx-auto">
<h1 class="text-2xl md:text-3xl font-bold header-text">Retina</h1>
<p class="mt-2 text-sm md:text-base subheader-text">
                30 Questions | 120 Total Marks | 40 min Duration | ~80.0 sec/question
            </p>
<button class="mt-2 bg-gray-200 text-gray-800 px-3 py-1 rounded-lg hover:bg-gray-300 transition dark:bg-gray-600 dark:text-white" id="theme-toggle">
                Toggle Dark Mode
            </button>
</div>
</header>
<!-- Instructions Section -->
<section class="container mx-auto p-4 md:p-6 section-transition" id="instructions">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-xl font-semibold mb-4">Instructions</h2>
<ul class="list-disc list-inside space-y-2 text-gray-700">
<li>This test contains 30 multiple choice questions.</li>
<li>Each question has only one correct answer.</li>
<li>You will have 40 minutes to complete the test.</li>
<li>Click or tap on an option to select your answer.</li>
<li>Use the "Mark for Review" button to revisit questions.</li>
<li>Navigate using Previous/Next buttons or the Questions Navigation panel.</li>
<li>Click "Submit" to finish and view results.</li>
<li>The test will auto-submit when time runs out.</li>
</ul>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="start-test">Start Test</button>


</div>
<div class="error-message hidden" id="error-message"></div>
</div>
</section>
<!-- Quiz Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="quiz">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<!-- Progress Bar -->
<div class="w-full bg-gray-200 rounded-full h-3 mb-4">
<div class="progress-bar h-3 rounded-full" id="progress-bar" style="width: 0%"></div>
</div>
<!-- Question Header -->
<div class="flex flex-col md:flex-row justify-between items-center mb-4">
<h2 class="text-lg font-semibold" id="question-number">Question <span>1</span> of 30</h2>
<p class="text-lg font-semibold mt-2 md:mt-0" id="timer">Time Remaining: <span>00:00</span></p>
</div>
<!-- Question Content -->
<div class="mb-6" id="question-content">
<p class="text-gray-800 mb-4" id="question-text"></p>
<div class="flex flex-wrap gap-4 mb-4" id="question-images"></div>
<div class="space-y-3" id="options"></div>
</div>
<!-- Navigation Buttons -->
<div class="flex flex-col md:flex-row justify-between items-center gap-2 md:gap-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition w-full md:w-auto" disabled="" id="previous-btn">Previous</button>
<button class="bg-yellow-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-yellow-400 transition w-full md:w-auto" id="mark-review">Mark for Review</button>
<button class="bg-blue-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="next-btn">Next</button>
<button class="bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full md:w-auto" id="nav-toggle">Questions Navigation</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="submit-test">Submit Test</button>
</div>
</div>
</section>
<!-- Results Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="results">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-2xl font-semibold mb-4">Retina - Results</h2>
<div class="grid grid-cols-1 md:grid-cols-2 gap-4 mb-6">
<p><strong>Correct:</strong> <span id="correct-count">0</span></p>
<p><strong>Wrong:</strong> <span id="wrong-count">0</span></p>
<p><strong>Unanswered:</strong> <span id="unanswered-count">0</span></p>
<p><strong>Marked for Review:</strong> <span id="marked-count">0</span></p>
</div>
<h3 class="text-lg font-semibold mb-4" id="result-question-number">Question <span>1</span> of 30</h3>
<div class="space-y-6" id="results-content"></div>
<div class="result-nav">
<button aria-label="Previous question result" class="result-nav-btn" disabled="" id="prev-result">Previous</button>
<button aria-label="Toggle results navigation panel" class="result-nav-btn" id="results-nav-toggle">Results Navigation</button>
<button aria-label="Next question result" class="result-nav-btn" id="next-result">Next</button>
</div>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="take-again">Take Again</button>
<button class="bg-gray-500 text-white px-6 py-2 rounded-lg hover:bg-gray-600 transition" id="review-test">Review Test</button>
</div>
</div>
</section>
<!-- Exit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="exit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Leave Test?</h2>
<p class="text-gray-700 mb-4">Your progress will be lost if you leave this page. Are you sure you want to exit?</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="continue-test">No, Continue</button>
<button class="bg-red-500 text-white px-4 py-2 rounded-lg hover:bg-red-600 transition" id="exit-test">Yes, Exit</button>
</div>
</div>
</div>
<!-- Submit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="submit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Confirm Submission</h2>
<p class="text-gray-700 mb-2">You have attempted <span id="attempted-count">0</span> of 30 questions.</p>
<p class="text-gray-700 mb-4"><span id="unattempted-count">0</span> questions are unattempted.</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="cancel-submit">Cancel</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-green-600 transition" id="confirm-submit">Submit Test</button>
</div>
</div>
</div>
<!-- Quiz Navigation Panel -->
<div class="fixed inset-y-0 right-0 nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="nav-panel">
<h2 class="text-lg font-semibold mb-4">Questions Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-nav">Close</button>
</div>
<!-- Results Navigation Panel -->
<div class="fixed inset-y-0 right-0 results-nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="results-nav-panel">
<h2 class="text-lg font-semibold mb-4">Results Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="results-nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="results-nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-results-nav">Close</button>
</div>
<!-- JavaScript Logic -->
<script>
        // Enable debug mode for detailed logging
        const DEBUG_MODE = true;

        // Log debug messages
        function debugLog(message) {
            if (DEBUG_MODE) {
                console.log(`[DEBUG] ${message}`);
            }
        }

        // Initialize questions with error handling
        let questions = [];
        let currentResultQuestion = 0; // State for current question in results
        try {
            debugLog("Attempting to parse questions_json");
            questions = [{"text": "Which drug causes the given presentation?", "options": [{"label": "A", "text": "Topical Steroids", "correct": false}, {"label": "B", "text": "Topical Beta Blockers", "correct": false}, {"label": "C", "text": "Topical PG Analogues", "correct": true}, {"label": "D", "text": "Topical Cycloplegics", "correct": false}], "correct_answer": "C. Topical PG Analogues", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture2_hPKDWFh.jpg"], "explanation_images": [], "explanation": "<p><strong>Ans. C) Topical PG Analogues</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A . Topical Steroids are used in the treatment of Cystoid Macular Edema .</li><li>â€¢ Option A</li><li>â€¢ Topical Steroids</li><li>â€¢ Cystoid Macular Edema</li><li>â€¢ Option B . Topical Beta Blockers are commonly used for glaucoma treatment and do not typically cause Cystoid Macular Edema. Their primary mechanism of action is reducing aqueous humor production in the eye .</li><li>â€¢ Option B</li><li>â€¢ Topical Beta Blockers</li><li>â€¢ glaucoma treatment</li><li>â€¢ primary mechanism</li><li>â€¢ action</li><li>â€¢ reducing aqueous humor production</li><li>â€¢ eye</li><li>â€¢ Option D . Topical Cycloplegics are used to paralyze the ciliary muscle and dilate the pupil . While they have various effects on the eye , they are not typically associated with causing Cystoid Macular Edema .</li><li>â€¢ Option D</li><li>â€¢ Topical Cycloplegics</li><li>â€¢ paralyze</li><li>â€¢ ciliary muscle</li><li>â€¢ dilate</li><li>â€¢ pupil</li><li>â€¢ eye</li><li>â€¢ causing Cystoid Macular Edema</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective</li><li>âž¤ Topical Prostaglandin Analogues can cause Cystoid Macular Edema .</li><li>âž¤ Topical Prostaglandin Analogues</li><li>âž¤ Cystoid Macular Edema</li><li>âž¤ Ref: KANSKI 9 TH EDITION PAGE 602</li><li>âž¤ Ref: KANSKI 9 TH EDITION PAGE 602</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The Amount of the Drug in this implant is:", "options": [{"label": "A", "text": "500 Âµg", "correct": false}, {"label": "B", "text": "700 Âµg", "correct": true}, {"label": "C", "text": "52 mg", "correct": false}, {"label": "D", "text": "36 mg", "correct": false}], "correct_answer": "B. 700 Âµg", "question_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture1_48C9Wuq.jpg"], "explanation_images": [], "explanation": "<p><strong>Ans. B) 700 Âµg</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ The above picture shows a Intravitreal Dexamethasone Implant . It is a sustainable release biodegradable implant used in treatment of Cytoid Macular Edema S econdary to Retinal Vein Occlusion , Diabetic Maculopathy and other causes. 0.7mg of Dexamethasone is incorporated into this Implant .</li><li>â€¢ The above picture shows a Intravitreal Dexamethasone Implant .</li><li>â€¢ Intravitreal Dexamethasone Implant</li><li>â€¢ It is a sustainable release biodegradable implant used in treatment of Cytoid Macular Edema S econdary to Retinal Vein Occlusion , Diabetic Maculopathy and other causes.</li><li>â€¢ sustainable release biodegradable implant</li><li>â€¢ Cytoid Macular Edema</li><li>â€¢ econdary</li><li>â€¢ Retinal Vein Occlusion</li><li>â€¢ Diabetic Maculopathy</li><li>â€¢ 0.7mg of Dexamethasone is incorporated into this Implant .</li><li>â€¢ 0.7mg</li><li>â€¢ Dexamethasone</li><li>â€¢ incorporated</li><li>â€¢ Implant</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective</li><li>âž¤ Intravitreal Dexamethasone Implant contains 700 mcg of Dexamethasaone .</li><li>âž¤ Intravitreal Dexamethasone Implant</li><li>âž¤ 700 mcg</li><li>âž¤ Dexamethasaone</li><li>âž¤ Ref: KANSKI 9 TH EDITION PAGE 521</li><li>âž¤ Ref:</li><li>âž¤ KANSKI 9 TH EDITION PAGE 521</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Ocriplasmin is used in treatment of:", "options": [{"label": "A", "text": "Diabetic Macular Edema", "correct": false}, {"label": "B", "text": "Keratoconus", "correct": false}, {"label": "C", "text": "Vitreomacular Traction", "correct": true}, {"label": "D", "text": "Primary Open Angle Glaucoma", "correct": false}], "correct_answer": "C. Vitreomacular Traction", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C) Vitreomacular Traction</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A . Diabetic Macular Edema (DME) is a complication of Diabetes characterized by Intraretinal Fluid Accumulation due to Microleakage from capillaries . Treatments for DME typically involve Anti-VEGF Injections, Corticosteroids , and Laser Therapy .</li><li>â€¢ Option A</li><li>â€¢ Diabetes</li><li>â€¢ Intraretinal Fluid Accumulation</li><li>â€¢ Microleakage</li><li>â€¢ capillaries</li><li>â€¢ Anti-VEGF Injections, Corticosteroids</li><li>â€¢ Laser Therapy</li><li>â€¢ Option B . Keratoconus is a Degenerative Disorder of the Cornea characterised by thinning and Ectasia which cause the Cornea to become Conical in shape . Treatment options for keratoconus include corneal cross-linking , custom soft contact lenses , and corneal transplant in advanced cases.</li><li>â€¢ Option B</li><li>â€¢ Degenerative Disorder</li><li>â€¢ Cornea</li><li>â€¢ thinning</li><li>â€¢ Ectasia</li><li>â€¢ Cornea</li><li>â€¢ become Conical</li><li>â€¢ shape</li><li>â€¢ keratoconus</li><li>â€¢ corneal cross-linking</li><li>â€¢ custom soft contact lenses</li><li>â€¢ corneal transplant</li><li>â€¢ Option D . The primary treatments for Primary Open Angle Glaucoma (POAG) are medications that reduce intraocular pressure , laser therapy , and surgical procedures .</li><li>â€¢ Option D</li><li>â€¢ Primary Open Angle Glaucoma (POAG)</li><li>â€¢ medications</li><li>â€¢ reduce intraocular pressure</li><li>â€¢ laser therapy</li><li>â€¢ surgical procedures</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective:</li><li>âž¤ Ocriplasmin is primarily used in the treatment of Vitreomacular Traction (VMT) . It works by enzymatically dissolving the proteins that cause the vitreous to adhere to the macula , thus relieving the traction that can impair vision .</li><li>âž¤ treatment</li><li>âž¤ Vitreomacular Traction (VMT)</li><li>âž¤ enzymatically dissolving</li><li>âž¤ proteins</li><li>âž¤ cause</li><li>âž¤ vitreous</li><li>âž¤ adhere</li><li>âž¤ macula</li><li>âž¤ relieving</li><li>âž¤ traction</li><li>âž¤ can impair vision</li><li>âž¤ Ref: KANSKI 9 TH EDITION PAGE 597</li><li>âž¤ Ref: KANSKI 9 TH EDITION PAGE 597</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The secondary vitreous concentrates the primary vitreous towards the center of the eye, creating the Canal of Cloquet, which contains a substance that is less optically dense than the secondary vitreous. Where is this secondary vitreous derived from?", "options": [{"label": "A", "text": "Surface Ectoderm", "correct": false}, {"label": "B", "text": "Neuroectoderm", "correct": true}, {"label": "C", "text": "Mesoderm", "correct": false}, {"label": "D", "text": "Paraxial Mesenchyme", "correct": false}], "correct_answer": "B. Neuroectoderm", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/screenshot-2024-01-29-140720.jpg"], "explanation": "<p><strong>Ans. B) Neuroectoderm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A . The surface ectoderm: contributes to several structures in the eye , such as the lens and cornea , but it is not the source of the secondary vitreous. The surface ectoderm mainly gives rise to structures at the very front of the eye .</li><li>â€¢ Option A</li><li>â€¢ The surface ectoderm:</li><li>â€¢ several structures</li><li>â€¢ eye</li><li>â€¢ lens</li><li>â€¢ cornea</li><li>â€¢ gives rise</li><li>â€¢ structures</li><li>â€¢ very front</li><li>â€¢ eye</li><li>â€¢ Option C . The mesoderm: contributes to various structures in the eye , including the sclera and the uveal tract ( iris , ciliary body , and choroid ), but it is not the source of the secondary vitreous.</li><li>â€¢ Option C</li><li>â€¢ The mesoderm:</li><li>â€¢ eye</li><li>â€¢ sclera</li><li>â€¢ uveal tract</li><li>â€¢ iris</li><li>â€¢ ciliary body</li><li>â€¢ choroid</li><li>â€¢ Option D . Paraxial mesenchyme contributes to structures in the orbit and extraocular muscles , but it does not give rise to the secondary vitreous in the eye.</li><li>â€¢ Option D</li><li>â€¢ Paraxial mesenchyme</li><li>â€¢ structures</li><li>â€¢ orbit</li><li>â€¢ extraocular muscles</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective</li><li>âž¤ The secondary vitreous of the eye is derived from the neuroectoderm .</li><li>âž¤ secondary vitreous</li><li>âž¤ eye</li><li>âž¤ neuroectoderm</li><li>âž¤ Ref: Pg 12/ COMPREHENSIVE Ophthalmology/ 6 th Edition/ AK KHURANA</li><li>âž¤ Ref:</li><li>âž¤ Pg 12/ COMPREHENSIVE Ophthalmology/ 6 th Edition/ AK KHURANA</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 55-year-old male patient, who is a known case of type 2 diabetes and recurrent myocardial infarction, presents to the ophthalmology clinic complaining of blurred vision in his left eye. He reports that his vision has gradually deteriorated over the past few months. Fundus examination reveals signs of diabetic retinopathy. OCT imaging confirms the presence of macular edema in the left eye. Based on the clinical scenario and findings, the patient is diagnosed with diabetic macular edema. Which is the intravitreal agent preferred in this case?", "options": [{"label": "A", "text": "Pegaptanib", "correct": false}, {"label": "B", "text": "Aflibercept", "correct": false}, {"label": "C", "text": "Triamcinolone Acetonide", "correct": true}, {"label": "D", "text": "Bevacizumab", "correct": false}], "correct_answer": "C. Triamcinolone Acetonide", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C) Triamcinolone Acetonide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A . An anti-VEGF ( Vascular Endothelial Growth Factor ) agent , Pegaptanib was one of the first agents of this class to be used for ocular conditions . However, it is not the most commonly used or preferred agent for DME due to its selective VEGF isoform binding .</li><li>â€¢ Option A</li><li>â€¢ anti-VEGF</li><li>â€¢ Vascular Endothelial Growth Factor</li><li>â€¢ agent</li><li>â€¢ Pegaptanib</li><li>â€¢ first agents</li><li>â€¢ ocular conditions</li><li>â€¢ preferred agent</li><li>â€¢ DME</li><li>â€¢ selective VEGF isoform binding</li><li>â€¢ Option B . Aflibercept is a widely used and highly effective anti-VEGF agent for the treatment of DME . Aflibercept has been shown to be effective in reducing macular edema and improving visual acuity in patients with DME . It binds all forms of VEGF-A , as well as placental growth factor , which are key in the pathogenesis of DME .</li><li>â€¢ Option B</li><li>â€¢ widely used</li><li>â€¢ highly effective anti-VEGF agent</li><li>â€¢ DME</li><li>â€¢ effective</li><li>â€¢ reducing macular edema</li><li>â€¢ improving visual acuity</li><li>â€¢ DME</li><li>â€¢ VEGF-A</li><li>â€¢ placental growth factor</li><li>â€¢ pathogenesis</li><li>â€¢ DME</li><li>â€¢ Option D Bevacizumab is another anti-VEGF agent used off-label for DME . It is effective in reducing macular edema and improving vision but is not FDA-approved for this indication. However, it is often used due to its cost-effectiveness .</li><li>â€¢ Option D</li><li>â€¢ another anti-VEGF agent</li><li>â€¢ off-label</li><li>â€¢ DME</li><li>â€¢ effective</li><li>â€¢ reducing macular edema</li><li>â€¢ improving vision</li><li>â€¢ due</li><li>â€¢ cost-effectiveness</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective</li><li>âž¤ In a patient with diabetic macular edema and a significant cardiac history , intravitreal steroid injection ( Triamcinolone acetonide / Dexamethasone implant ) is a preferred choice due to its effectiveness in treating DME and a favourable safety profile .</li><li>âž¤ diabetic macular edema</li><li>âž¤ significant cardiac history</li><li>âž¤ intravitreal steroid injection</li><li>âž¤ Triamcinolone acetonide</li><li>âž¤ Dexamethasone implant</li><li>âž¤ effectiveness</li><li>âž¤ treating DME</li><li>âž¤ favourable safety profile</li><li>âž¤ Ref: KANSKI 9 TH EDITION PAGE 508</li><li>âž¤ Ref:</li><li>âž¤ KANSKI 9 TH EDITION PAGE 508</li><li>âž¤ 2. Giridhar S, Verma L, Rajendran A, Bhende M, Goyal M, Ramasamy K, Rajalakshmi, Padmaja R, Natarajan S, Palanivelu MS, Raman R, Sivaprasad S. Diabetic macular edema treatment guidelines in India: All India Ophthalmological Society Diabetic Retinopathy Task Force and Vitreoretinal Society of India consensus statement. Indian J Ophthalmol. 2021 Nov;69(11):3076-3086. doi: 10.4103/ijo.IJO_1469_21. PMID: 34708746; PMCID: PMC8725123.</li><li>âž¤ 2. Giridhar S, Verma L, Rajendran A, Bhende M, Goyal M, Ramasamy K, Rajalakshmi, Padmaja R, Natarajan S, Palanivelu MS, Raman R, Sivaprasad S. Diabetic macular edema treatment guidelines in India: All India Ophthalmological Society Diabetic Retinopathy Task Force and Vitreoretinal Society of India consensus statement. Indian J Ophthalmol. 2021 Nov;69(11):3076-3086. doi: 10.4103/ijo.IJO_1469_21. PMID: 34708746; PMCID: PMC8725123.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Recommended daily supplementation based on AREDS2 includes all except:", "options": [{"label": "A", "text": "Zinc", "correct": false}, {"label": "B", "text": "Vitamin E", "correct": false}, {"label": "C", "text": "Beta-Carotene", "correct": true}, {"label": "D", "text": "Lutein", "correct": false}], "correct_answer": "C. Beta-Carotene", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. C) Beta-Carotene</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A . Zinc is included in the AREDS2 formula . It plays a role in maintaining the health of the retina and may help slow the progression of AMD .</li><li>â€¢ Option A</li><li>â€¢ AREDS2 formula</li><li>â€¢ role</li><li>â€¢ maintaining</li><li>â€¢ health</li><li>â€¢ retina</li><li>â€¢ slow</li><li>â€¢ progression</li><li>â€¢ AMD</li><li>â€¢ Option B . Vitamin E is also part of the AREDS2 formula . It is an antioxidant that helps protect cells in the body , including those in the eye , from damage .</li><li>â€¢ Option B</li><li>â€¢ AREDS2 formula</li><li>â€¢ antioxidant</li><li>â€¢ protect cells</li><li>â€¢ body</li><li>â€¢ eye</li><li>â€¢ from damage</li><li>â€¢ Option D . Lutein, along with zeaxanthin , replaced beta-carotene in the AREDS2 formula . These carotenoids are believed to be beneficial for eye health , particularly in reducing the risk or slowing the progression of AMD .</li><li>â€¢ Option D</li><li>â€¢ zeaxanthin</li><li>â€¢ replaced beta-carotene</li><li>â€¢ AREDS2 formula</li><li>â€¢ carotenoids</li><li>â€¢ beneficial</li><li>â€¢ eye health</li><li>â€¢ reducing</li><li>â€¢ risk</li><li>â€¢ slowing</li><li>â€¢ progression</li><li>â€¢ AMD</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective</li><li>âž¤ Based on the findings of AREDS2 , the recommended daily supplementation for age-related macular degeneration includes zinc , vitamin E , and lutein , but not beta-carotene, which was removed due to its associated risks , particularly in smokers .</li><li>âž¤ AREDS2</li><li>âž¤ recommended daily supplementation</li><li>âž¤ age-related macular degeneration</li><li>âž¤ zinc</li><li>âž¤ vitamin E</li><li>âž¤ lutein</li><li>âž¤ removed</li><li>âž¤ associated risks</li><li>âž¤ smokers</li><li>âž¤ Ref: KANSKI 9 TH EDITION PAGE 576</li><li>âž¤ Ref:</li><li>âž¤ KANSKI 9 TH EDITION PAGE 576</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Fenretinide is a new agent under trial for which of the following conditions?", "options": [{"label": "A", "text": "Retinitis Pigmentosa", "correct": false}, {"label": "B", "text": "Diabetic Retinopathy", "correct": false}, {"label": "C", "text": "Central Retinal Vein Occlusion", "correct": false}, {"label": "D", "text": "Age related Macular Degeneration", "correct": true}], "correct_answer": "D. Age related Macular Degeneration", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. D) Age related Macular Degeneration</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective:</li><li>âž¤ Fenretinide is a new drug under clinical trial in ARMD . Visual cycle modulation occurs by ameliorating the formation of cytotoxic products by reducing the rate of vitamin A processing .</li><li>âž¤ Fenretinide is a new drug under clinical trial in ARMD .</li><li>âž¤ Fenretinide</li><li>âž¤ new drug</li><li>âž¤ clinical trial</li><li>âž¤ ARMD</li><li>âž¤ Visual cycle modulation occurs by ameliorating the formation of cytotoxic products by reducing the rate of vitamin A processing .</li><li>âž¤ Visual cycle modulation</li><li>âž¤ ameliorating</li><li>âž¤ formation</li><li>âž¤ cytotoxic products</li><li>âž¤ reducing</li><li>âž¤ rate</li><li>âž¤ vitamin A processing</li><li>âž¤ Ref: KANSKI 9 TH EDITION PAGE 576</li><li>âž¤ Ref:</li><li>âž¤ KANSKI 9 TH EDITION PAGE 576</li><li>âž¤ 2. Taskintuna I, Elsayed ME, Schatz P. Update on Clinical Trials in Dry Age-related Macular Degeneration. Middle East Afr J Ophthalmol. 2016 Jan-Mar;23(1):13-26. doi: 10.4103/0974-9233.173134. PMID: 26957835; PMCID: PMC4759891.</li><li>âž¤ 2. Taskintuna I, Elsayed ME, Schatz P. Update on Clinical Trials in Dry Age-related Macular Degeneration. Middle East Afr J Ophthalmol. 2016 Jan-Mar;23(1):13-26. doi: 10.4103/0974-9233.173134. PMID: 26957835; PMCID: PMC4759891.</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following Anti â€“ VEGF binds with placental growth factor?", "options": [{"label": "A", "text": "Pegaptanib", "correct": false}, {"label": "B", "text": "Aflibercept", "correct": true}, {"label": "C", "text": "Ranibizumab", "correct": false}, {"label": "D", "text": "Bevacizumab", "correct": false}], "correct_answer": "B. Aflibercept", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B) Aflibercept</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A . Pegaptanib is an anti-VEGF medication that selectively binds to VEGF-165 isoform . However, it does not bind to placental growth factor.</li><li>â€¢ Option A</li><li>â€¢ Pegaptanib</li><li>â€¢ anti-VEGF medication</li><li>â€¢ selectively binds</li><li>â€¢ VEGF-165</li><li>â€¢ isoform</li><li>â€¢ Option C . Ranibizumab ( Lucentis ) is a monoclonal antibody fragment that binds to and inhibits VEGF-A . It does not bind to placental growth factor.</li><li>â€¢ Option C</li><li>â€¢ Ranibizumab</li><li>â€¢ Lucentis</li><li>â€¢ monoclonal antibody fragment</li><li>â€¢ binds</li><li>â€¢ inhibits VEGF-A</li><li>â€¢ Option D . Bevacizumab ( Avastin ) is a full-length monoclonal antibody that binds to VEGF-A but, like Ranibizumab and Pegaptanib, does not bind to placental growth factor.</li><li>â€¢ Option D</li><li>â€¢ Bevacizumab</li><li>â€¢ Avastin</li><li>â€¢ full-length monoclonal antibody</li><li>â€¢ binds</li><li>â€¢ VEGF-A</li><li>â€¢ Ranibizumab</li><li>â€¢ Pegaptanib,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective</li><li>âž¤ Aflibercept is unique among the listed anti-VEGF agents in that it binds both to VEGF-A and placental growth factor . This dual binding ability is relevant in its use for treating conditions like wet age-related macular degeneration and diabetic macular edema , where both VEGF and placental growth factor play a role in pathogenesis .</li><li>âž¤ Aflibercept</li><li>âž¤ unique</li><li>âž¤ listed anti-VEGF agents</li><li>âž¤ binds both</li><li>âž¤ VEGF-A</li><li>âž¤ placental growth factor</li><li>âž¤ dual binding ability</li><li>âž¤ relevant</li><li>âž¤ wet age-related macular degeneration</li><li>âž¤ diabetic macular edema</li><li>âž¤ both VEGF</li><li>âž¤ placental growth factor</li><li>âž¤ pathogenesis</li><li>âž¤ Ref: KANSKI 9 TH EDITION PAGE 587</li><li>âž¤ Ref:</li><li>âž¤ KANSKI 9 TH EDITION PAGE 587</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 45-year-old male patient with a history of pulmonary tuberculosis presents to the ophthalmology clinic for a routine eye examination. The patient has been on ATT since 4 months. Which type of colour defect is associated with ethambutol, an ATT drug?", "options": [{"label": "A", "text": "Red Desaturation", "correct": false}, {"label": "B", "text": "Blue-Green Defect", "correct": false}, {"label": "C", "text": "Green Desaturation", "correct": false}, {"label": "D", "text": "Red-Green Defect", "correct": true}], "correct_answer": "D. Red-Green Defect", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. D) Red-Green Defect</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A . Red Desaturation is not typically associated with ethambutol. Red desaturation is more commonly associated with optic nerve disorders like optic neuritis .</li><li>â€¢ Option A</li><li>â€¢ not typically associated</li><li>â€¢ optic nerve disorders</li><li>â€¢ optic neuritis</li><li>â€¢ Option B . Blue-Green Defect: Ethambutol toxicity can lead to a blue-yellow color vision defect . Blue-yellow defect is the earliest colour defect to develop in ethambutol toxicity , however red-green defect is the commonest .</li><li>â€¢ Option B</li><li>â€¢ Ethambutol toxicity</li><li>â€¢ lead</li><li>â€¢ blue-yellow color vision defect</li><li>â€¢ Blue-yellow defect</li><li>â€¢ earliest colour defect</li><li>â€¢ develop</li><li>â€¢ ethambutol toxicity</li><li>â€¢ red-green defect</li><li>â€¢ commonest</li><li>â€¢ Option C . Green Desaturation: This type of color defect is not typically associated with ethambutol toxicity.</li><li>â€¢ Option C</li><li>â€¢ not typically</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective</li><li>âž¤ Ethambutol , an antitubercular therapy drug , is commonly associated with a red-green color vision defect .</li><li>âž¤ Ethambutol</li><li>âž¤ antitubercular therapy</li><li>âž¤ drug</li><li>âž¤ red-green color</li><li>âž¤ vision defect</li><li>âž¤ Ref: PARSONS DISEASES OF EYE 22 ND EDITION PAGE 244</li><li>âž¤ Ref:</li><li>âž¤ PARSONS DISEASES OF EYE 22 ND EDITION PAGE 244</li><li>âž¤ 2. Saxena R, Singh D, Phuljhele S, Kalaiselvan V, Karna S, Gandhi R, Prakash A, Lodha R, Mohan A, Menon V, Garg R. Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy. Indian J Ophthalmol. 2021 Dec;69(12):3734-3739. doi: 10.4103/ijo.IJO_3746_20. PMID: 34827033; PMCID: PMC8837289</li><li>âž¤ 2. Saxena R, Singh D, Phuljhele S, Kalaiselvan V, Karna S, Gandhi R, Prakash A, Lodha R, Mohan A, Menon V, Garg R. Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy. Indian J Ophthalmol. 2021 Dec;69(12):3734-3739. doi: 10.4103/ijo.IJO_3746_20. PMID: 34827033; PMCID: PMC8837289</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Maximum allowed dosage of hydroxychloroquine to avoid development of Bullâ€™s eye maculopathy is?", "options": [{"label": "A", "text": "4.5mg/kg/day", "correct": true}, {"label": "B", "text": "5.5mg/kg/day", "correct": false}, {"label": "C", "text": "6.5mg/kg/day", "correct": false}, {"label": "D", "text": "7/5mg/kg/day", "correct": false}], "correct_answer": "A. 4.5mg/kg/day", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. A) 4.5mg/kg/day</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ As per the American Academy of Ophthalmology Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy - 2016 , the limit for maximum daily HCQ use is < 5.0 mg/kg real weight , which correlates better with risk than ideal weight . There are no similar demographic data for CQ, but dose comparisons in older literature suggest using <2.3 mg/kg real weight. Screening for toxicity: A baseline fundus examination should be performed to rule out preexisting maculopathy . Annual screening after 5 years for patients on acceptable doses and without major risk factors . Screening Tests: The primary screening tests are automated visual fields plus spectral-domain optical coherence tomography (SD OCT). These should look beyond the central macula in Asian patients . The multifocal electroretinogram (mfERG) can provide objective corroboration for visual fields , and fundus autofluorescence (FAF) can show damage topographically. Modern screening should detect retinopathy before it is visible in the fundus</li><li>â€¢ As per the American Academy of Ophthalmology Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy - 2016 , the limit for maximum daily HCQ use is < 5.0 mg/kg real weight , which correlates better with risk than ideal weight . There are no similar demographic data for CQ, but dose comparisons in older literature suggest using <2.3 mg/kg real weight.</li><li>â€¢ American Academy of Ophthalmology</li><li>â€¢ Chloroquine</li><li>â€¢ Hydroxychloroquine Retinopathy</li><li>â€¢ maximum daily HCQ</li><li>â€¢ < 5.0 mg/kg real weight</li><li>â€¢ correlates</li><li>â€¢ risk</li><li>â€¢ than</li><li>â€¢ ideal weight</li><li>â€¢ Screening for toxicity: A baseline fundus examination should be performed to rule out preexisting maculopathy .</li><li>â€¢ baseline fundus examination</li><li>â€¢ performed</li><li>â€¢ rule out preexisting maculopathy</li><li>â€¢ Annual screening after 5 years for patients on acceptable doses and without major risk factors .</li><li>â€¢ Annual screening</li><li>â€¢ after 5 years</li><li>â€¢ acceptable</li><li>â€¢ doses</li><li>â€¢ without major risk factors</li><li>â€¢ Screening Tests: The primary screening tests are automated visual fields plus spectral-domain optical coherence tomography (SD OCT). These should look beyond the central macula in Asian patients .</li><li>â€¢ automated visual fields</li><li>â€¢ spectral-domain optical coherence tomography (SD OCT).</li><li>â€¢ beyond</li><li>â€¢ central macula</li><li>â€¢ Asian patients</li><li>â€¢ The multifocal electroretinogram (mfERG) can provide objective corroboration for visual fields , and fundus autofluorescence (FAF) can show damage topographically.</li><li>â€¢ multifocal electroretinogram (mfERG)</li><li>â€¢ objective corroboration</li><li>â€¢ visual fields</li><li>â€¢ fundus autofluorescence (FAF)</li><li>â€¢ damage topographically.</li><li>â€¢ Modern screening should detect retinopathy before it is visible in the fundus</li><li>â€¢ Modern screening</li><li>â€¢ detect retinopathy</li><li>â€¢ before</li><li>â€¢ visible</li><li>â€¢ fundus</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective</li><li>âž¤ Maximum allowed dosage of hydroxychloroquine to avoid development of Bullâ€™s eye maculopathy is 4.5mg/kg/day .</li><li>âž¤ avoid</li><li>âž¤ Bullâ€™s eye maculopathy</li><li>âž¤ 4.5mg/kg/day</li><li>âž¤ Ref: PARSONS DISEASES OF EYE 22 ND EDITION PAGE 367</li><li>âž¤ Ref:</li><li>âž¤ PARSONS DISEASES OF EYE 22 ND EDITION PAGE 367</li><li>âž¤ 2. https://www.aao.org/education/clinical-statement/revised-recommendations-on-screening-chloroquine-h</li><li>âž¤ 2.</li><li>âž¤ https://www.aao.org/education/clinical-statement/revised-recommendations-on-screening-chloroquine-h</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The location of the fovea is described as being 2 DD away from the optic disc. What is the normal Disc Diameter (DD)?", "options": [{"label": "A", "text": "1.5 mm", "correct": true}, {"label": "B", "text": "2 mm", "correct": false}, {"label": "C", "text": "2.5 mm", "correct": false}, {"label": "D", "text": "3 mm", "correct": false}], "correct_answer": "A. 1.5 mm", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture3_eCOmSlZ.jpg"], "explanation": "<p><strong>Ans. A) 1.5 mm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ The diameter of the optic disc is 1.5mm .</li><li>â€¢ diameter</li><li>â€¢ optic disc</li><li>â€¢ 1.5mm</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective:</li><li>âž¤ The size of the optic disc is 1.5mm</li><li>âž¤ size</li><li>âž¤ 1.5mm</li><li>âž¤ Ref: Pg 166/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>âž¤ Ref:</li><li>âž¤ Pg 166/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "How much is the diameter of the Macula Lutea?", "options": [{"label": "A", "text": "2.5 mm", "correct": false}, {"label": "B", "text": "3.5 mm", "correct": false}, {"label": "C", "text": "4.5 mm", "correct": false}, {"label": "D", "text": "5.5 mm", "correct": true}], "correct_answer": "D. 5.5 mm", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture4_aUcZQQS.jpg"], "explanation": "<p><strong>Ans. D) 5.5 mm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ The Diameter of Macula Lutea is 5.5 mm .</li><li>â€¢ Diameter</li><li>â€¢ Macula Lutea</li><li>â€¢ 5.5 mm</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective:</li><li>âž¤ The size of the macula lutea is 5.5 mm.</li><li>âž¤ size</li><li>âž¤ macula lutea</li><li>âž¤ 5.5 mm.</li><li>âž¤ Ref: Pg 167 / Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>âž¤ Ref:</li><li>âž¤ Pg 167 / Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The Fovea centralis is responsible for the visual acuity of a person. How much is its diameter?", "options": [{"label": "A", "text": "1 mm", "correct": false}, {"label": "B", "text": "1.5 mm", "correct": true}, {"label": "C", "text": "2.5 mm", "correct": false}, {"label": "D", "text": "3.5 mm", "correct": false}], "correct_answer": "B. 1.5 mm", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture5_PD4Fgy1.jpg"], "explanation": "<p><strong>Ans. B) 1.5 mm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ The diameter of fovea is 1.5 mm .</li><li>â€¢ diameter</li><li>â€¢ fovea</li><li>â€¢ 1.5 mm</li><li>â€¢ Ref: Pg 167 / Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>â€¢ Ref:</li><li>â€¢ Pg 167 / Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The insertion of which of these muscles is closest to the macula?", "options": [{"label": "A", "text": "Inferior Oblique", "correct": true}, {"label": "B", "text": "Inferior Rectus", "correct": false}, {"label": "C", "text": "Levator Palpebrae Superioris", "correct": false}, {"label": "D", "text": "Superior Rectus", "correct": false}], "correct_answer": "A. Inferior Oblique", "question_images": [], "explanation_images": ["https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture6_JofgII5.jpg"], "explanation": "<p><strong>Ans. A) Inferior Oblique</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option B . The inferior rectus muscle inserts on the anterior , inferior surface of the eye . It moves the eye downward .</li><li>â€¢ Option B</li><li>â€¢ anterior</li><li>â€¢ inferior surface</li><li>â€¢ eye</li><li>â€¢ eye downward</li><li>â€¢ Option C . Levator Palpebrae Superioris is responsible for elevating the upper eyelid and does not directly influence eye movement or attachment to the eyeball in a way that would bring it close to the macula.</li><li>â€¢ Option C</li><li>â€¢ elevating</li><li>â€¢ upper eyelid</li><li>â€¢ Option D . Inserting on the anterior , superior surface of the eyeball , the superior rectus elevates the eye .</li><li>â€¢ Option D</li><li>â€¢ anterior</li><li>â€¢ superior surface</li><li>â€¢ eyeball</li><li>â€¢ elevates</li><li>â€¢ eye</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>âž¤ Educational Objective</li><li>âž¤ When considering the anatomical relationship between the extraocular muscles and the macula , the inferior oblique muscle inserts posterior to the equator of the eye while the rectii insert anterior to the equator of the eye .</li><li>âž¤ extraocular muscles</li><li>âž¤ macula</li><li>âž¤ inferior oblique muscle</li><li>âž¤ posterior</li><li>âž¤ equator</li><li>âž¤ rectii insert</li><li>âž¤ anterior</li><li>âž¤ equator</li><li>âž¤ eye</li><li>âž¤ Ref: Pg 360/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>âž¤ Ref:</li><li>âž¤ Pg 360/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>âž¤ 2. https://eyewiki.org/Extraocular_Muscles</li><li>âž¤ 2.</li><li>âž¤ https://eyewiki.org/Extraocular_Muscles</li></ul>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Henleâ€™s Layer is the thickened Outer Plexiform Layer in which of the following region?", "options": [{"label": "A", "text": "Parafoveal", "correct": false}, {"label": "B", "text": "Foveal", "correct": true}, {"label": "C", "text": "Optic disc", "correct": false}, {"label": "D", "text": "Periphery", "correct": false}], "correct_answer": "B. Foveal", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Ans. B) Foveal</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>â€¢ Explanation:</li><li>â€¢ Option A . The parafoveal area is the region surrounding the fovea. While it is a significant part of the macula and has a high density of photoreceptors , Henle